Novel Bio-spectrum Technologies, Inc. (NBT) is a start-up biotechnology company located in the United States in Tampa Florida. NBT is a resident at the Tampa Bay Technology Incubator (TBTI) which is part of USF (University of South Florida) Research Park (subdivision of USF-CONNECT). NBT’s business model includes five components where the main component is to develop diagnostic lab tests related to cancer, diabetes, and Alzheimer’s disease.
Component 1: CANCER, DIABETES AND ALZHEIMER'S DIAGNOSTIC PRODUCTS
To ensure exclusivity and world-wide use, any diagnostic product NBT plans to develop will be based on existing patents, and on new method-patents that would result during the development of each diagnostic product. NBT will start with a USF portfolio of undeveloped Intellectual Properties (IPs) related to cancer, diabetes, and Alzheimer's disease. With respect to cancer, the portfolio will include biomarkers for brain, breast, lung, prostate, colon, ovarian, etc. Several of the IPs involve the family of proteins PKC (Protein Kinase C). NBT’s approach for the development of each IP-based product is to first make collaborations with the original inventors and apply for SBIR and/or any other applicable grants where funding is from government agencies, Non-Profit Organizations (NPOs), or any other funding entities.
Currently, NBT has Licensing Agreements with USF for a patent in brain tumors, a patent in breast cancer, a written first right of refusal for a patent in kidney neuroblastoma and another in diabetes, and is negotiating for several more IP's.
Component 2: Research Services
The second component of the NBT business model involves the engagement of NBT in several ventures related to research such as consulting, clinical studies, and other research studies where NBT provides services based on its expertise.
Some of the services include experiment design, cloning, western blots, cell culture, and others. The goal is to generate prompt and reliable revenue streams to support partly NBT's first component. For the current calendar year, NBT projects a 20% growth compared to revenue generated in the previous calendar year.